PepGen Q2 FY26 net loss narrows 22.84% to $17.81 million
PEPG•Q2 FY26 earnings and expenses
PepGen posted a net loss of $17.81 million, narrowing from $23.09 million a year earlier.
Operating loss narrowed to $18.94 million from $23.93 million, as research and development expense fell 31.91% to $12.52 million.
General and administrative expense rose 15.81% to $6.42 million, while interest income increased 29.81% to $1.09 million.
Cash position and FREEDOM2 update
Cash, cash equivalents and marketable securities totaled $117.2 million; PepGen expects funding into the fourth quarter of 2027.
FREEDOM2 remains on partial U.S. clinical hold; 10 mg/kg cohort data are expected in November 2026, with 12.5 mg/kg results in H1 2027.
